Encouraging Results Published On Use Of TomoTherapySM In Lung Cancer Treatment

TomoTherapy Incorporated (NASDAQ: TOMO) cited recently published encouraging preliminary results of an ongoing Phase I clinical trial on the use of intensity-modulated (IMRT) and image-guided radiation therapy (IGRT) focusing on the concept of accelerated hypofractionation to overcome tumor repopulation, one of the well-known mechanisms of radiation resistance, using TomoTherapySM for non-small cell lung cancer (NSCLC).

More: continued here

Filed under: Clinical Trials on April 15th, 2009